Alkermes (NASDAQ:ALKS) used its presentation at the J.P. Morgan Healthcare Conference to outline its positioning entering ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Alkermes (ALKS) is a stock that can certainly grab the attention ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak ...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF ...

What Changed in the Alkermes Price Target Alkermes just saw its fair value estimate nudged from about US$43.88 to US$43.81 per share, a very small trim that reflects only a modest reset in assumptions ...

Alkermes (ALKS) shifts to fully integrated biopharma, leveraging Vibrance-2, Lybalvi growth, and Avadel buy to de-risk ...

An announcement from Alkermes ( (ALKS) ) is now available.

As stripped down and divested Alkermes enters 2024 as a “pure-play neuroscience company”—as described by CEO Richard Pops on a conference call on Thursday—much will depend on the success of new ...

Instead of the garden-variety symphony music favored by most pharma companies before entering a conference call, Alkermes selected Fleetwood Mac’s breakup anthem “Go Your Own Way.” It was a clever way ...

Alkermes completed the separation of its oncology business into spin-off Mural Oncology, the drugmaker announced Wednesday. Mural made its formal debut Thursday, with the independent company beginning ...

This year, we’re celebrating 15 years of “Alkermes in Action,” our employee-led volunteer program that supports local non-profit organizations through hands-on activities. This month, more than 200 ...